Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
- Birklé, S.
- Desselle, A.
- Chaumette, T.
- Gaugler, M.-H.
- Cochonneau, D.
- Fleurence, J.
- Dubois, N.
- Hulin, P.
- Aubry, J.
- Paris, F.
DOIAbstract
International audienceCurrent antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models. © 2013 Landes Bioscience
Add to ORKG